- Investing Ideas
- /
- Austrian Pharmaceuticals & Biotech Potentially Undervalued Companies
Austrian Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Jul 01, 2022
Companies with a Value score of at least 3, ordered by Value score
29 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BMRNBioMarin Pharmaceutical | US$80.58 | 0% | 13.5% | US$15.3b | US$110.46 | PE389.6x | E47.8% | n/a | ||
| LUNH. Lundbeck | kr.23.20 | 5.0% | -10.4% | kr.34.3b | n/a | PE5.7x | E25.8% | n/a | ||
| PFEPfizer | US$49.66 | 3.2% | 48.5% | US$294.2b | US$53.99 | PE11.6x | E-18.0% | 3.1% | ||
| REGNRegeneron Pharmaceuticals | US$567.50 | -0.9% | 15.1% | US$63.7b | US$652.09 | PE8x | E-3.2% | n/a | ||
| GILDGilead Sciences | US$59.44 | 1.1% | 1.7% | US$77.5b | US$66.98 | PE17.2x | E8.3% | 4.7% | ||
| UCBUCB | €82.74 | 2.0% | -8.0% | €15.6b | €109.58 | PE14.8x | E9.5% | 1.6% | ||
| BIIBBiogen | US$198.88 | 1.0% | -32.4% | US$30.8b | US$229.23 | PE21.3x | E2.3% | n/a | ||
| ESFEurofins Scientific | €78.90 | 0% | -17.8% | €14.4b | €108.64 | PE19.3x | E-0.2% | 1.3% | ||
| MRKMerck | US$87.40 | -0.1% | 32.0% | US$233.7b | US$91.34 | PE16.8x | E11.8% | 3.0% | ||
| GXIGerresheimer | €58.20 | -11.2% | -38.0% | €1.8b | €91.93 | PE21.3x | E20.9% | 2.2% | ||
| IQVHIQVIA Holdings | US$205.40 | 1.4% | -1.6% | US$40.7b | US$250.61 | PE37.7x | E18.6% | 0% | ||
| ABBVAbbVie | US$145.14 | 0.7% | 49.6% | US$271.8b | US$153.04 | PE21.9x | E-0.6% | 3.7% | ||
| QGENQiagen | US$45.44 | 4.4% | 9.7% | US$10.7b | US$54.22 | PE19.9x | E7.0% | n/a | ||
| AMGNAmgen | US$234.10 | 1.3% | 11.4% | US$131.2b | US$235.01 | PE22.9x | E9.7% | 3.2% | ||
| TEVATeva Pharmaceutical Industries | US$7.12 | -3.5% | -12.4% | US$8.8b | US$8.92 | PB0.9x | E105.1% | 0% | ||
| MRCKMERCK Kommanditgesellschaft auf Aktien | €166.05 | 0.4% | 1.9% | €72.0b | €210.79 | PE22.6x | E6.3% | 1.1% | ||
| GRFGrifols | €18.50 | -1.6% | -17.2% | €10.9b | €22.04 | PE69.2x | E30.4% | 1.9% | ||
| BAYNBayer | €57.13 | -0.9% | 11.0% | €56.3b | €79.07 | PE25.6x | E8.7% | 3.5% | ||
| MARIMarinomed Biotech | €71.00 | 3.5% | -43.0% | €106.6m | €128.50 | PS9.2x | E65.4% | n/a | ||
| DHRCDanaher | US$240.25 | -0.6% | 4.4% | US$181.5b | US$307.31 | PE29.2x | E7.4% | 0.4% | ||
| VRTXVertex Pharmaceuticals | US$272.80 | 0.5% | 60.7% | US$73.5b | US$279.35 | PE30x | E10.3% | n/a | ||
| JNJJohnson & Johnson | US$170.68 | -0.9% | 21.1% | US$467.1b | US$180.07 | PE23.6x | E4.4% | 2.5% | ||
| MTDMettler-Toledo International | US$1,087.00 | -0.2% | n/a | US$26.4b | US$1,214.28 | PE33.2x | E7.9% | n/a | ||
| TMOFThermo Fisher Scientific | US$511.30 | 0.2% | 18.6% | US$212.7b | US$622.98 | PE28x | E9.1% | 0.2% |